GenStar Therapeutics merged with Vascular Genetics to form Autus Genetics, Corp that focuses on the development of gene therapy for cardiovascular disease. Under the merger, each company shareholders will own about 50% of the new company and Vascular Genetics is expected to receive 38 million newly issued GenStar shares.